Gritstone

Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO

Retrieved on: 
星期二, 五月 31, 2022
Oxaliplatin, DNA, Annual general meeting, Ipilimumab, U.S. Securities and Exchange Commission, Survival, Progression-free survival, Patient, Vaccine, Bevacizumab, Society, Circulating tumor DNA, American Society of Clinical Oncology, Bristol Myers Squibb, Safety, ASCO, Large-cell lung carcinoma, Degenerative disease, Colorectal cancer, Maintenance, Nivolumab, Immune system, ESMO, Security (finance), Neoplasm, GLOBE, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy, to treat advanced solid tumors. Additionally, the company announced it is presenting a “Trial in Progress” poster summarizing the Phase 2/3 GRANITE-CRC-1L- study (randomized study for first-line maintenance treatment of metastatic, microsatellite stable colorectal cancer) at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Additionally, the company announced it is presenting a Trial in Progress poster summarizing the Phase 2/3 GRANITE-CRC-1L- study (randomized study for first-line maintenance treatment of metastatic, microsatellite stable colorectal cancer) at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
  • This study enrolled and treated 26 patients as of ESMO 2021 presentation with previously treated, metastatic solid tumors including patients with colorectal cancer, gastroesophageal adenocarcinoma, and non-small cell lung cancer.
  • The Phase 3 portion will further measure the clinical efficacy of the regimen as assessed by progression-free survival using iRECIST criteria.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

Gritstone to Participate in H.C. Wainwright Global Investment Conference

Retrieved on: 
星期二, 五月 17, 2022
U.S. Securities and Exchange Commission, Degenerative disease, Vaccine, Security (finance), Immune system, Conference, Investor, GLOBE, Pharmaceutical industry, Gritstone

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the worlds most potent vaccines.

Key Points: 
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the worlds most potent vaccines.
  • We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders

Retrieved on: 
星期一, 五月 2, 2022
COVID-19, SLATE, Immune system, Immunology, GLOBE, CEPI, NIH, Bill & Melinda Gates Foundation, IR, Program, Neoplasm, HIV, Coalition for Epidemic Preparedness Innovations, Cancer, Annual report, Coalition, National, Epidemic, Gilead Sciences, Antigen, Infection, La Jolla Institute for Immunology, U.S. Securities and Exchange Commission, RNA transfection, CORAL, Bill, Cell, Pharmaceutical industry, Online shopping, Gritstone

Shareholders can email [email protected] for any support inquiries.

Key Points: 
  • Shareholders can email [email protected] for any support inquiries.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期三, 四月 27, 2022
Antigen, Immune system, Cyprus Securities and Exchange Commission, Employment, Program, CEPI, SLATE, Coalition, Bill, GLOBE, Coalition for Epidemic Preparedness Innovations, Epidemic, HIV, COVID-19, Cell, Neoplasm, Cancer, CORAL, La Jolla Institute for Immunology, Annual report, Security (finance), Bill & Melinda Gates Foundation, RNA transfection, National, Infection, Board, Immunology, NIH, Gilead Sciences, Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Gritstones 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery

Retrieved on: 
星期二, 四月 12, 2022
Bristol Myers Squibb, Epitope, Human, DNA, CEPI, Coalition for Epidemic Preparedness Innovations, NIH, Public, U.S. Securities and Exchange Commission, COVID-19, Association, Security (finance), Gilead Sciences, Annual report, Nivolumab, CORAL, GLOBE, Program, National, Patient, Infection, Artificial intelligence, Cell, Neoplasm, TSNA, NSCLC, Trial of the century, Vaccine, Antigen, Immune system, Coalition, Bill, SLATE, Bill & Melinda Gates Foundation, ChAdOx1, La Jolla Institute for Immunology, HLA, American Association, RNA transfection, Circulating tumor DNA, HIV, KRAS, AACR, Epidemic, Immunology, Survival, Ipilimumab, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, delivered three presentations (one oral and two posters) further supporting the potential of its novel vaccine development capabilities and delivery platforms to develop transformational therapeutic cancer vaccines at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The collective data we presented at AACR reinforce our expertise in designing and delivering potent vaccines, and support the optimization of antigen cassette design, dose and vaccine regimen as key tools to induce differentiated immune response, said Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone.
  • Oral Presentation: Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back
    SLATE v1* was well-tolerated and demonstrated a favorable safety profile in all subjects dosed (n=26).
  • Gritstone subsequently developed a second, optimized product candidate (SLATE-KRAS) that exclusively includes epitopes from mutated KRAS.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期三, 三月 30, 2022
Cell, National, Coalition for Epidemic Preparedness Innovations, Epidemic, CEPI, La Jolla Institute for Immunology, Board, Vaccine, Bill, Program, Antigen, Neoplasm, Cancer, Cyprus Securities and Exchange Commission, CORAL, Employment, Immunology, Security (finance), Immune system, Gilead Sciences, Infection, NIH, RNA transfection, COVID-19, GLOBE, Coalition, HIV, SLATE, Bill & Melinda Gates Foundation, Annual report, Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Gritstones 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting

Retrieved on: 
星期二, 三月 8, 2022
HIV, AACR, National, Epitope, CEPI, Immune system, U.S. Securities and Exchange Commission, Cell, Bill & Melinda Gates Foundation, Bill, CORAL, Infection, KRAS, Abstract (summary), Antigen, Human, Coalition for Epidemic Preparedness Innovations, GLOBE, La Jolla Institute for Immunology, Doctor of Philosophy, Patient, Security (finance), Neoplasm, American Association, 2021 Essex County Council election, Epidemic, NIH, Gilead Sciences, COVID-19, Coalition, SLATE, Association, Immunology, Review, American Association for Cancer Research, Pharmaceutical industry, Vaccine, Gritstone

EMERYVILLE, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, Louisiana. In the poster presentations, Gritstone representatives will review data from individualized neoantigen program, GRANITE, and the “off-the-shelf" neoantigen vaccine program, SLATE. In the oral presentation, Christine D Palmer, PhD will discuss how immunodominant human T cell responses to tumor specific neoantigens presented by the same HLA in a first-generation construct informed development of a second-generation candidate that exhibits immunogenic superiority over version 1 in preclinical models within SLATE. This optimized candidate, SLATE-KRAS, exclusively includes KRASmut epitopes and is now in Phase 2 testing in solid tumor patients.

Key Points: 
  • In the poster presentations, Gritstone representatives will review data from individualized neoantigen program, GRANITE, and the off-the-shelf" neoantigen vaccine program, SLATE.
  • This optimized candidate, SLATE-KRAS, exclusively includes KRASmut epitopes and is now in Phase 2 testing in solid tumor patients.
  • Abstracts associated with these presentations are now available on the conference website .
  • The companys lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an off-the-shelf shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.

Gritstone to Participate in Cowen 42nd Annual Health Care Conference

Retrieved on: 
星期四, 二月 24, 2022
GLOBE, Cell, Investor, Neoplasm, Bill, Time, Coalition, NIH, Gritstone, Immune system, Bill & Melinda Gates Foundation, COVID-19, Infection, National, Epidemic, CORAL, Antigen, La Jolla Institute for Immunology, Gilead Sciences, SLATE, CEPI, Coalition for Epidemic Preparedness Innovations, Cancer, Conference, Immunology, HIV, Vaccine

EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the Infectious Disease panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.

Key Points: 
  • EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the Infectious Disease panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.
  • ET
    A live webcast of the panel will be accessible via the Investors & Media section of the companys website at https://ir.gritstonebio.com/investors/events .
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期二, 二月 8, 2022
GLOBE, Employment, Cyprus Securities and Exchange Commission, Board, Cell, Immune system, Cancer, HIV, Infection, NIH, National, La Jolla Institute for Immunology, Security (finance), CORAL, CEPI, Antigen, Coalition for Epidemic Preparedness Innovations, Neoplasm, Coalition, Bill, Epidemic, Immunology, SLATE, Bill & Melinda Gates Foundation, Gilead Sciences, COVID-19, Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Gritstones 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Gritstone undertakes no obligation to update or revise any forward-looking statements.

Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference

Retrieved on: 
星期二, 二月 8, 2022
GLOBE, Gritstone, Conference, Cell, Immune system, Cancer, Gilead Sciences, HIV, Infection, Washington Marriott Marquis, NIH, National, La Jolla Institute for Immunology, EST, CORAL, CEPI, Antigen, Marriott Marquis, Coalition for Epidemic Preparedness Innovations, Neoplasm, BIO, Coalition, Bill, Epidemic, Immunology, SLATE, Bill & Melinda Gates Foundation, COVID-19, Pharmaceutical industry

The panel, titled "Treating Cancer Through Precision Oncology", will take place from 11 a.m. to 11:45 a.m. EST Monday, February 14, 2022, and will be accessible live to conference registrants.

Key Points: 
  • The panel, titled "Treating Cancer Through Precision Oncology", will take place from 11 a.m. to 11:45 a.m. EST Monday, February 14, 2022, and will be accessible live to conference registrants.
  • An archived replay will be added to https://ir.gritstonebio.com/investors/events approximately 30 days after the event.
  • For additional information on the BIO CEO & Investor Conference, visit http://www.bio.org/events/bio-ceo-investor-conference .
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.